Keeping Pace with Real-World Evidence: Evolving Software Regulations and the Growing Application of Artificial Intelligence

Whether you are in development or ready for commercialization, real-world data solutions can be used to help navigate complex regulatory pathways and decision-making. Download this white paper from IQVIA – an associate member of AdvaMed® – to explore the increasing spotlight on the use of real world evidence, what regulators are looking for, and how AI-powered applications are rising in the field of digital health from code to commercialization.
Related Reading
Resource / Artificial Intelligence (AI) / Regulatory Affairs
Comments on FDA’s PMA eSTAR Draft Guidance
November 17, 2026
In this AdvaMed® Comment Letter to FDA, AdvaMed responds to the agency’s draft guidance on the electronic submission template (eSTAR) for premarket approval (PMA) applications. With eSTAR set to become mandatory for PMAs, AdvaMed calls for a template that keeps today’s flexibility, handles large files, and is built and updated through a clear, open, and predictable process. These changes would help medtech companies prepare complete submissions and help FDA review them more efficiently.
Resource / Artificial Intelligence (AI)
Modernizing the Milkman: AI’s New Playbook for Medtech Commercial Excellence
November 11, 2026
BCG explores how AI is transforming medtech commercial operations, from customer engagement and sales to pricing and service.
Resource / Digital Health / Global & Trade / Regulatory Affairs
EY Pulse of the MedTech Industry Report 2026
November 5, 2026
The 20th edition of the EY Pulse of the MedTech Industry Report captures the medical devices sector at both a high point and a turning point.
Resource / Digital Health
AdvaMed’s Response to the GenAI Discussion Paper
October 30, 2026
AdvaMed submits comments to FDA on the regulation of generative AI-enabled medical devices, urging a risk-based approach that builds on existing frameworks to advance innovation and protect patients.
News / Digital Health / Health Access / Regulatory Affairs
AdvaMed Digital Health Tech Board Approves Best Practices to Advance Responsible Data Access and Patient Care
October 28, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that its Digital Health Tech Board of Directors has approved voluntary Data Access Principles & Best Practices to help medical technology companies and health systems collaborate on responsible data access, use, and protection. The framework puts patient trust at the center of efforts to improve care, support research, and advance innovation, including artificial intelligence.
News / AdvaMed Advancements / Artificial Intelligence (AI) / Coverage & Payment / Diabetes / Diagnostics / Digital Health / Global & Trade / Health Access / Investor Relations / Medical Imaging / Orthopedic / Regulatory Affairs / Tariffs / The MedTech Conference / Value-Based Collaborations
AdvaMed Concludes Record-Breaking MedTech Conference 2026
October 28, 2026
BOSTON—AdvaMed, the Medtech Association, concluded The MedTech Conference 2026, convening more than 4,470 attendees from 2,050 companies from 40 countries for the global medtech industry’s premier annual gathering.
Resource / Digital Health
Data Access Principles & Best Practices
October 27, 2026
Access AdvaMed’s guidance framework designed to help stakeholders navigate data access considerations across the connected healthcare ecosystem.
News / Artificial Intelligence (AI) / Regulatory Affairs
AdvaMed Encourages Risk-Based FDA Approach to Generative AI Medical Devices
October 27, 2026
WASHINGTON—AdvaMed, the Medtech Association, encouraged the U.S. Food and Drug Administration (FDA) to build on its existing regulatory framework for generative AI (GenAI)-enabled medical devices rather than create new frameworks that could impede the innovations serving patients. The comments respond to FDA’s discussion paper (Docket No. FDA-2026-N-7874) seeking early input on assessing risks and evaluating GenAI devices before marketing and post-market monitoring.